Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A.

Rovi was founded in 1946 by Juan López-Belmonte Lozano as a pharmaceutical laboratory in Madrid, Spain. The company went public on the Madrid Stock Exchange in 1952 and remains controlled by the López-Belmonte family. The current president and CEO, Juan López-Belmonte López, is the third generation to run the firm. Wealth originates from pharmaceutical manufacturing and sales across Spain and Latin America, though the family has not disclosed a separate office structure. Rovi operates as a fully integrated pharmaceutical company involved in research, development, manufacturing, and commercialization of drugs. Its portfolio includes the top-selling low-molecular-weight heparin Bemiparin (Hibor) and the Roxane brand of immediate-release oral dosage forms. Since 2021, Rovi has served as the fill-finish manufacturing partner for Moderna's COVID-19 vaccine in Spain, a contract that accounted for roughly 40% of 2023 revenue (per Rovi annual report, 2023). The company invests in specialty injectable drugs, biosimilars, and drug-device combination products. Geographically, Rovi sells across 50+ countries, with primary markets in Europe, Latin America, and the Middle East. The company employs approximately 2,500 people, including a dedicated R&D site in Granada. Rovi maintains production facilities in Madrid and Granada (Spain) and a joint venture factory in Lima, Peru for the Latin American market. In May 2024, Rovi announced the acquisition of a proprietary pipeline of peptide-based drugs from a European biotech for €75M (per Rovi press release, May 2024). The López-Belmonte family owns roughly 55% of the company (per Rovi 2024 annual report), giving them majority control without a separate family-office vehicle publicly documented. Rovi's dual identity as a publicly traded company and a family-controlled business is its core structural differentiator. The López-Belmonte family has maintained both operational management and board control since founding, avoiding a standard single-family-office model. The company's strong cash flow from contract manufacturing supports direct investment in its own pipeline, rather than relying on external venture funding. Succession is legally structured through family ownership of shares, with the CEO role passing to the third generation.